ADVANCE

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (ADVANCE)

What's the purpose of the trial?

This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the standard care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).

Trial status

Accepting patients

Phase
Phase 2
Enrollment
462
Last Updated
2 weeks ago
Am I Eligible

Participating Centers

There are 7 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Carfilzomib
  • Daratumumab
  • Dexamethasone
  • Lenalidomide

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.